Nurix Therapeutics, Inc. (NRIX): Total Assets
$688.13M
As of 2025-11-30
$535.54M
As of 2026-05-31
+18.2%
3-year compound annual growth
+11.7%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-11-30 | $688.13M | +2.8% | 2026-01-28, Balance as of period end |
| 2024-11-30 | $669.34M | +88.2% | 2026-01-28, Balance as of period end |
| 2023-11-30 | $355.60M | -14.7% | 2025-01-28, Balance as of period end |
| 2022-11-30 | $416.76M | -12.6% | 2024-02-15, Balance as of period end |
| 2021-11-30 | $476.77M | +20.3% | 2023-02-09, Balance as of period end |
| 2020-11-30 | $396.34M | +799.8% | 2022-01-28, Balance as of period end |
| 2019-11-30 | $44.05M | n/a | 2021-02-16, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Nurix Therapeutics, Inc. (NRIX) | 2025-11-30 | $688.13M | +2.8% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $327.65M | -6.7% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $567.75M | -7.3% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $271.15M | -21.2% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $323.15M | +0.4% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $1.42B | +1.6% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $92.11M | +21.0% |
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $151.57M | +25.7% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $1.36B | -0.3% |
Compare NRIX, SPRY, LAB, ARCT side by side · Screen every company in Pharmaceutical Preparations ↗